Oncology Research2026，Vol.34Issue(7)：P.357-369,13.DOI:10.32604/or.2026.077700
Progression-Free Survival with PARP Inhibitors According to Clinical Risk in Patients with Ovarian Cancer:An Indirect Comparison Using Reconstructed Data
Lorenzo Gasperoni 1Luna Del Bono 2Alberto Farolfi 3Andrea Messori 4Vera Damuzzo5
作者信息
- 1. Pharmaceutical Department,USL Toscana Centro,Prato,Italy
- 2. Department of Pharmacy,School of Specialization in Hospital Pharmacy,University of Pisa,Pisa,Italy
- 3. Medical Oncology,Breast&GYN Unit,IRCCS Istituto Romagnolo per lo Studio dei Tumori(IRST)“Dino Amadori”,Meldola,Italy
- 4. HTA Unit,Regional Health Service,Firenze,Italy Italian Society of Clinical Pharmacy and Therapeutics(SIFaCT),Torino,Italy
- 5. Italian Society of Clinical Pharmacy and Therapeutics(SIFaCT),Torino,Italy Hospital Pharmacy Department,Azienda Ulss 2 Marca Trevigiana,Treviso,Italy
- 折叠
摘要
关键词
IPDfromKM/poly(ADP-ribose)polymerase(PARP)inhibitors/advanced ovarian cancer/indirect comparison分类
医药卫生引用本文复制引用
Lorenzo Gasperoni,Luna Del Bono,Alberto Farolfi,Andrea Messori,Vera Damuzzo..Progression-Free Survival with PARP Inhibitors According to Clinical Risk in Patients with Ovarian Cancer:An Indirect Comparison Using Reconstructed Data[J].Oncology Research,2026,34(7):P.357-369,13.
